Overview

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Status:
COMPLETED
Trial end date:
2024-12-07
Target enrollment:
Participant gender:
Summary
Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics
Phase:
PHASE1
Details
Lead Sponsor:
Cassava Sciences, Inc.
Treatments:
Simufilam